Research Analysts Offer Predictions for Celcuity Q1 Earnings

Celcuity Inc. (NASDAQ:CELC - Free Report) - Research analysts at HC Wainwright cut their Q1 2025 earnings per share (EPS) estimates for shares of Celcuity in a report released on Tuesday, April 1st. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($1.01) per share for the quarter, down from their previous estimate of ($0.67). HC Wainwright currently has a "Buy" rating and a $27.00 target price on the stock. The consensus estimate for Celcuity's current full-year earnings is ($2.62) per share. HC Wainwright also issued estimates for Celcuity's Q2 2025 earnings at ($1.04) EPS, Q3 2025 earnings at ($1.07) EPS, Q4 2025 earnings at ($1.10) EPS, FY2025 earnings at ($4.23) EPS, FY2026 earnings at ($4.22) EPS, FY2027 earnings at ($0.82) EPS, FY2028 earnings at $1.50 EPS and FY2029 earnings at $3.63 EPS.

Separately, Needham & Company LLC reaffirmed a "buy" rating and set a $29.00 price objective on shares of Celcuity in a research note on Tuesday, April 1st. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Celcuity has a consensus rating of "Buy" and a consensus price target of $30.17.

Celcuity Trading Down 10.9 %

NASDAQ:CELC traded down $1.00 during trading hours on Thursday, reaching $8.16. The company's stock had a trading volume of 114,708 shares, compared to its average volume of 287,726. The company has a debt-to-equity ratio of 0.65, a quick ratio of 10.36 and a current ratio of 10.35. The firm has a market capitalization of $308.77 million, a price-to-earnings ratio of -3.13 and a beta of 0.44. The firm has a 50-day simple moving average of $10.95 and a 200-day simple moving average of $12.70. Celcuity has a 1 year low of $7.70 and a 1 year high of $20.15.

Celcuity (NASDAQ:CELC - Get Free Report) last posted its quarterly earnings results on Monday, March 31st. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.13).

Institutional Investors Weigh In On Celcuity

Several institutional investors have recently added to or reduced their stakes in CELC. Summit Investment Advisors Inc. raised its stake in shares of Celcuity by 49.5% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,421 shares of the company's stock valued at $45,000 after acquiring an additional 1,132 shares during the last quarter. Aquatic Capital Management LLC purchased a new position in Celcuity during the 4th quarter valued at about $50,000. GAMMA Investing LLC raised its position in Celcuity by 1,237.4% during the 1st quarter. GAMMA Investing LLC now owns 1,324 shares of the company's stock valued at $131,000 after purchasing an additional 1,225 shares during the last quarter. The Manufacturers Life Insurance Company purchased a new stake in Celcuity in the 4th quarter worth approximately $142,000. Finally, Bleakley Financial Group LLC bought a new stake in shares of Celcuity in the 4th quarter worth approximately $146,000. Hedge funds and other institutional investors own 63.33% of the company's stock.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.